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Abstract-The purpose of this paper is mainly the coefficient identification of a phar- 
macokinetic two-compartment open model with first-order absorption. This model con- 
sists of the central compartment (plasma) and the peripheral one (tissue) containing the 
ill site aimed by the action of the administered drug. 
The different phenomenons taking place between the compartments obey a tirst- 
order (linear) kinetic. This phenomenons of absorption, transfer, and elimination are 
characterized by their rate constants. A compartmental analysis leads to a system of 
coupled linear differential equations whose coefficients, the unknowns of the problem, 
are the above-mentioned rate constants. This system describes the transition of the drug 
from its administration to its action site passing through the plasma. 
An oral administration of a single dose is considered and the evolution of the drug 
concentration in the plasma is measured. These measurements, performed over time 
in a reduced number on the rabbit, give unique and useful information for the identi- 
fication of the coefficient set appearing in the mathematical model. 
The identification problem is stated in terms of a constraint minimization of a cost 
functional, given by the quadratic error between the measured and the computed drug 
concentrations in the plasma. From the nonconvexity of this cost functional (existence 
of more than one local minimum) follows the nonuniqueness of the optimal solution of 
this identification problem. The minimization is performed on a minicomputer by means 
of a nonlinear programming method of conjugate-gradient ype. 
The efficiency of the suggested method has been tested with measurements made 
on a lot of rabbits after the administration of a single dose (100 mg/kg) of aspirin in 
form of lysine acetylsalicylate and sodium salicylate. The administration was made, 
thanks to an adapted technique, by a rubber probe in two different ways: in the stomach 
and in the duodenum. After the model identification it was possible to study, in simu- 
lation on a computer, the effect of the metabolite/nonmetabolite drug forms as well as 
the effect of the drug administration site on the time course of the drug in the organism. 
This simulation makes it easy to have acces to magnitudes, familiar to the phar- 
maceutical practitioner, like the half-life, the bioavailability, the clearances. the build- 
up of blood levels for multiple doses, etc. . . It was possible to improve the under- 
standing of the time course of aspirin in rabbit in comparison to the time course of its 
main metabolite, the sodium salicylate, and this for the same animal. 
* This article is the reviewed version of a paper presented at the IASTED International Symposium AC1 83. 
Copenhagen, June 2%July 1, 1983. 
1245 
1746 W. GEISZ AND ht. BOKRIS 
1. INTRODUCTION 
Some years ago the study of a drug was particularly given by its pharmacodynamic prop- 
erties[l]. These properties were the action of the drug on the isolated organ or the whole 
animal. It was also supposed that a mean dosage may be sufficient. But later it was noticed 
that the drug development modalities are not the same for different subjects submitted 
to the same treatment. This ascertainment led to a new discipline-pharmacokinetics[2]. 
Pharmacokinetics allows an adequate study of the time course of a drug and this as a 
function of the particular characteristics of the body which the drug was administered. 
The drug repartition in the body is given by its nature and localisation as well as by the 
distribution rate of this repartition. The pharmacokinetics finally permits one to obtain a 
mathematical model of the time course of a drug. This mathematical representation roots 
on the concepts of the compartment and of the compartmental analysis. 
The compartment is a volume of the body; considered to be homogenous and that all 
the molecules of a given substance are submitted to the same condition. Each compartment 
is characterized by an apparent distribution volume and a concentration. 
The compartmental analysis consists in finding a simple mathematical model consistent 
with the experimental data as well as with the physiological reality. 
This model allows a computer simulation for the study of the time course of the drug 
in different parts of the body, with the basic interest to know what happens in the inac- 
cessible parts. It is also possible to reduce in this way a great number of experimental 
data to a few number of standardised magnitudes, familiar to the physician; to forecast 
experimental results and to design optimal therapeutic treatments. 
The purpose of this paper is mainly the coefficient identification of a pharmacokinetic 
two-compartment open model with first-order absorption. We compare the administration 
of lysine acetylsalicylate with sodium salicylate by two different ways: stomach or duo- 
denum in the same rabbits. 
2. METHODS 
2.1. Drug administration 
Lysine acetylsalicylate and sodium salicylate are administered by two ways in rabbits: 
with a rubber probe directly in the stomach, with a rubber probe chronically implanted 
in the duodenum. 
Experiments are performed in cross over, for each way of administering we used the 
same rabbit. 
Blood samples are obtained by veinure punction in lo-16 different instants over a time 
interval of 7- 15 hours. 
Afterwards we measure the blood salicylic levels by a fluorimetric[3]. With this method 
it is possible to compare the biodisponibility of each salicylate preservation and to un- 
derstand the role of the stomach in resorption. 
2.2. Mathematical model 
The considered model is a two-compartmental one, obeying a first-order kinetic, with 
a drug administration in the gastro-intestinal tract. 
We are considering the case of a single dose D administered at the time t = 0. 
The two compartments are 1) the central compartment containing the plasma and the 
abundantly vascularized organs, and 2) the peripheric compartment given by the tissues. 
We admit for the moment that the drug elimination takes place from both compartments. 
h pharmacokinetic two-compartment model 1217 
With the assumptions[4] made above, one obtains schematically the two-compartment 
model (Fig. 1) and the corresponding mathematical model is 
dQa(t) 
- = - kzQa(t), 
dt 
O<F< 1, Q,(O) = F*D 
dQ, Cl) 
- = kzQa(t) + kz,Qz(t) - (k,z + ke,,)Q,(f)r 
dt 
Q,(O) = 0 
dQz(t) -= 
dt k,zQ,(t) - (kz, +- k,z)Qz(t), Qz(O) = 0 
(1) 
where V,, VZ are the apparent distribution volumes of the central and the peripheral 
compartments (1); Qa, Q,, Q2 are the drug amounts on the administration site, in the 
blood and in the tissuelar compartment (mg); C,, C, , Cz are the drug concentrations on 
the administration site, in the blood and in the tissuelar compartment (mgil), k, is the 
absorption rate constant, strictly positive (h-l); k,,, , ke,? are the elimination rate con- 
stants, both strictly positive or one of them equal to zero (h-l); klz, k2, are the transfer 
rate constants between the central and the peripheral compartments, both strictly positive 
(h-l). 
It is well-known[4] that only the amount F.D < D of the administered drug reaches 
the central compartment; the other part of the dose D is eliminated on a nonrenal way 
(e.g. metabolization, fecal and sudoral elimination, etc. . .). Knowing that 
Qa(t) = F.D exp( - k,t), C,(t) = Q,(t)lV, 
and eliminating Q*(t) in the last two equations of (I), we get the following second-order 
differential equation provided with its initial conditions 
d’C, 
dt’ (t) + P % (t) + qC,(t) = n. exp(-k,t) 
dC, (0) k,F*D -=_ 
dt VI 
C,(O) = 0 
(2) 
with p = k12 + k2, + k,,, + kc,*; q = k12ke12 + k2,ke,, + ke,,ke12; a = k,(k,, + kc,: 
- k,)F*Dl V, . 
A discriminant analysis of the characteristic equation associated to the expression (I), 
shows the existence of two real and distinct solutions rl, r2. Moreover these solutions 
are strictly positive because q is strictly positive. 
Fig. I. Two-compartment model 
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Consequently, Eq. (2) admits a real and unique solution, which may be written as 
c,(t) = BI exp(-r,t) + BZ exp(-rzt) + B3 exp(-r3t), (3) 
where 
BI = (kaF*DIV~)-(k2~ + kelz - r,)l((k, - r,) (rz - r,)), 
B2 = (k,F.DIV1)*(kzl + k,lz - rz)l((k, - t-2) (r, - r?)), 
B3 = (LF*DIVl)*(kzl + kelz - k,)l((k, - rl) (k, - rz)), 
r3 = k,. 
The initial condition C,(O) = 0 is equivalent to B1 + B2 + B3 = 0 so that (3) may be 
written as 
Cl(t) = B,(exp(-rlt) - exp(-r3t)) + B2(exp(-rzr) - exp(-r3t)). (4) 
2.3. Identification problem 
The measurements Ci(tj), j = 1, . . . , M, we dispose are only a reduced number M 
of the drug concentrations at the blood level. It is hardly conceivable to make measure- 
ments on the tissue level. 
Let us write the criterion 
W, r) = ; 2 (CI@, r; fj) - d,ttj))'t (3 
-J=t 
where rT = (r1r2r3), BT = (BIB2) given by the quadratic error between the computed 
and the measured drug concentrations in the plasma. The identification problem is to find 
a parameter set B and r minimizing this quadratic difference. 
The mathematical statement of the deterministic identification problem is 
Find the vectors B* and r* so that 
J(B*, r*> = inf J(B, r). 
G-0 
(6) 
The quadratic criterion is convex with regard to B but nonconvex in relation to r. This 
nonconvexity expresses the fact that the functional J possesses several local minima which 
induces the nonuniqueness of the solution r* [j]. 
The computed solution r*, depends on the initialization r” if an iterative minimization 
method is used. This is schematically illustrated in Fig. 2. 
So, it is necessary to make a good choice of r’. 
The resolution of this identification problem is made in two steps: minimization in 
relation with B and minimization in relation with r. 
Let us suppose to be at the iteration number k + 1. Knowing rk from the preceding 
iteration k it is possible to compute Bk” so that 
A.Bk+’ = e 
I? (2: = (C,(h) .** d,(f&f)), (7) 
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Fig. 2. Nonconvex function of a single variable. 
where A is a rectangular matrix (M x 2) with the elements 
C7ji = exp( - rf’tj) - exp( - r$‘fi), i = 1.2andj = 1,. . . ,.\I. 
The effective calculation of the solutions B ‘- ’ of the linear overdetermined system (7) 
is obtained thanks to a least square method which applies Householder’s triangularization 
method. 
Next, r’+ ’ is computed by minimization of the criterion (5). This minimization is carried 
out by the conjugate gradient method. To do so, this method needs an analytic expression 
of the gradient of (5) with regard to r: 
VJ,k + 1 = 
j= I 
M 
-B$” c r,.e(Bl”‘, rk-‘; fj).exp(-r$+‘.fj) 
j=l 
,M 
(Bt” + B$“) z tj.e(Bk”, rkt’; tj)*exp(-r$-“tj) 
j= I 
. 
(8) 
where e(B’+‘, r’+‘; tj) = Cl(Bkf’, r’+‘; b) - Cl(tj). 
This convergent iteration method is stopped at an iteration number n if the relative 
precision of the computed solution is reached giving finally the optimal solutions B* = 
B” and r* = r”. 
Remark. A good starting value r0 is given by a quick measurement analysis in the 
semilogarithmic plan considering the residual method[6]. 
It is possible now to compute, via simple algebraic relations, the rate constants of the 
pharmacokinetic model. 
The computed plasmatic concentration may be put in the form 
CI (t) = B, exp( -at) + Bx,, exp( - k,,r) + B, exp( - pr) (9) 
with the choice 
CL = Max(rT, r;, I-;) and B = Min(rr, t-2*, rz) 
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expressed in [41. 
The choice of B,, Bkfl, B, among BT, I?;, Bz is given by the choice of CI, k,, p, choice 
operating on the whole term contaming one of these exponents. 
The real, distinct, and positive solutions of the characteristic equation of (2) are chosen 
to be (Y and p. 
We assume in the following that the drug elimination occurs only from the central 
compartment, so that kelz = 0. 
Taking into account the analytic expressions of B, and BP it is possible to write 
kz, = (B,@ka + Bp.ct*k, + Bk;ci$)I(B;(ko - u) + Bp.(k, - PII, 
k ~II = a.Plkz,, 
k,z = a + p - k2, - k,,, , 
F.DIV, = (B,(k, - cd + BB(k, - P))lk,,. 
(10) 
Relation (IO) gives the parameters involved in the pharmacokinetic model and herewith 
it is easy now to begin a simulation study of the different drug amounts QO. Q, , Q2. 
Remark. When elimination occurs also from the peripheral compartment then we 
have to deal with a nonidentifiability problem. The system parameters become identifiable 
if supplementary information is provided by complementary measurements or by a hy- 
pothesis[7]. The latter possibility is used when the knowledge of Vz is required. 
3. RESULTS 
3.1. Blood level measurements 
The data are obtained after the administration of 100 mg/kg of the two drugs by the 
two different ways. The blood concentrations are expressed in salicylic acid. 
The first two columns of Table I show an example of data r, CI obtained after the 
administration of lysine acetylsalicylate in the duodenum. 
3.2. Validation of the identification algorithm 
The validation has been made with experimental data collected on a lot of rabbits. 
The identification algorithm was implemented on a minicomputer. The corresponding 
software (in Fortran) needs a memory size of 20 Kbytes and its execution time is inferior 
to a second. 
The algorithm has been tested on a multitude of numerical examples, here we discuss 
only one of them. The experimental data considered here are those of the preceding section 
3.1. 
The initialization of the algorithm was chosen to be r’l = 1.2, ri = 0.85, r; = 0.4. 
Table 2 shows the decrease of the criterion magnitude (5) with regard to the iteration 
numbers. The relative accuracy of the optimal solutions of (6) was taken to be 10e6. 
The identified parameters are the following: 
k, = 0.4288, kc,, = 2.9970, klz = 3.7315, 
kz, = 1.0378, F.DIV, = 4546.28 (mg/l). 
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Table 1. 1Measured and computed blood concentrations 6,. CI 
c (h) i S, (ma/l) i CL (ma/l) i C,-il (=I 
_____________:___‘_________ _____________ -____________ 
0 o . 
_____________:_____________. 
u 0 
0.25 ; 236.14 ; _____________:_____________ 220.63. -2.33 : 
-____________ _____________ 
0.50 ; 273.80 
_____________:_____________ 
i 270.53 -1.17 : 
_____________ __-__-__-____ _______------ ------_______ 
0.75 : 279.62 ’ 279.36 : -0.09 
_____________:_____________: _____________:_____________ 
1.00 : 270.11 : 280.02 ; 3.67 
_____________:_____________:_______------ ------_______ 
1.25 ; 263.89 ; 277.lh ’ 2.68 
_____________ _____________ _________--:-__________ 
2.25 ; 252.27 ’ ; 247.08 -2.05 
-_-__________ _------------ _______---:_____________ 
2.75 : 227.57 : 
-____-______-:_____________ 
; 226.37 -0.52 
3.25 ’ 209.60 
_________-+____________ 
_____________:____________- 
; 204.51 -2.46 
_____________:____________ 
4.00 : 175.86 ’ 172.09 : -2.14 
_____________:_____________: _______---:_____________ 
5.00 : 135.40 : 
_____________:____-___----- 
; 132.86 -1.8; 
_____________:_____________ 
7.00 ; 60.54 ; 74.13 ; 22.05 
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A proof of the identification quality is given by the last two columns of Table 1. The 
difference between the computed concentration C, and the measured one C, is less than 
4%, except the last point at 7 hours. The nonuniqueness of the solution, obtained by the 
minimization of Eq. (5) has been also shown numerically by choices of the initializations 
I-’ quite different from the choice taken above. For little differences in the choice of r” 
the computed solutions are quite the same, what differs is only the iteration number. 
3.3. Simulation results and their discussion 
Once, knowing the system parameters of the mathematical model (1) it is easy to 
undertake a simulation study of this model. This study has been made on the same digital 
minicomputer as the identification, by means of a finite difference discretization method 
and so enables the time plot of data directly from the differential equations. Our simulation 
software allows a single or a multiple dose study, considering different doses and admin- 
istration intervals or not, as well as various graphic possibilities. On the other hand it 
supplies the pharmaceutical practitioner with magnitudes familiar to him, and defined in 
[4], like the half life, the bioavailability, the clearances, the buildup of blood levels for 
multiple doses, etc. . . . 
Tables 3 and 4 show an example of simulation results for two rabbits 1 and 2 for V2 
= VI. Notatrons tlzabs, t12+ are the half-life of the drug on the administration site and 
in the plasma (h); AUC (= air under the curve) is the amount of the administered drug 
dose that reaches the general circulation for t E (0, 2) (mg x h/l); Clmax, CZmax are the 
concentration maxima in the central and peripheral compartment (mg/l); tImax, rZmax are 
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Table 3. Case of lysine acetylsalicylate 
jwml +U-rz: 
______ _---_: 
t12& 2.2714 ; 2.5136 ; 
---__ __-_-_ ________ 
AUC : : lM5.5 ; 16X.6 ; s 
w-e- __-___-_ ________ 
Cl& 2l1.84 
I--- -----~-‘_-_- 
‘Imax: : 1.80 : I.65 in 
----_ ;_______ ________ 
c12+ 2.3716 ; 2.5182 ; A 
----- __--- _____-__ 
C : 26318 :C 
_,z% :__e%f_ :____:_- : H 
=2max : : 3.675 ; 6.W i 
_-___ __-__-__ ___a____ __ 
_____ ________ ________ __ 
;RA&m1j~2~ 
________ -------- 
y&b ; 1.m ; 1.6699 ; 
--__a- me_--_ ________ 
NC ; 1878.8 ; 1CGO.6 ; s 
_____ -______:-____-_’ 
C : 282.43 : 167.65 
.T 
lmar : :0 _____ ________*_-------* 
rlmax : : 1.65 ; I.83 It4 
C : lM.32 : 175.67 : U 
_zzx :----: _______ : 
: 16% : 2.175 ” 
t_2max_ L_L____ :_____-_:_. 
_____ ________ _--__-__ _~ 
Table 4. Case of sodium salicylate 
the instants corresponding to Crmax and Czmax (h); Fn. Fs are the fractions of the drug 
reaching the plasma for an administration in the duodenum and in the stomach; Cln, CIs 
are the total body clearances for the administration of the drug in the duodenum and in 
the stomach (l/h), respectively. 
The bioavailability is defined by the AUC and the drug absorption rate. This rate is 
assumed to be of first order and given by the absorption half-life. 
The total body clearance is the ratio between the drug quantity (mg) reaching the general 
circulation and the AUC (mg x h/l). 
The following discussion refers to some results shown in Tables 3 and 4, and is made 
for the same rabbit in function of the drug and the administration site. 
The absorption half-lives for the same drug are greater in the stomach than in the 
duodenum, The sodium salicylate absorption is faster than the lysine acetylsalicylate one. 
The AUC for the lysine acetylsalicylate administration in the stomach is greater than 
the AUC for the same drug administered in the duodenum. In the case of sodium salicylate 
the opposite ascertainment is true. The bioavailability is more important for the sodium 
salicylate than for the lysine acetylsalicylate. On the other hand, the bioavailability is the 
highest in the case of sodium salicylate administered in the duodenum. 
The maximum of the drug level in the blood C imax is for both drugs greater for an 
administration in the duodenum than for an administration in the stomach; the corre- 
sponding time tImax shows the opposite tendency. 
The drug half-life in the plasma tlZelp is longer for an administration in the duodenum 
as for an administration in the stomach. These times differ significantly for the admin- 
istration of the two drugs in the duodenum; t12elp for the sodium salicylate is 2 to 3 times 
greater as tlZerp for the lysine acetylsalicylate. 
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The total body clearances for an administration in the duodenum CID seem to be less 
than the same clearances for a stomach administration CIS. 
The fractions of the drug reaching the plasma (F s, Fn) are mainly a function of the 
experimentation subject (rabbit). 
4. CONCLUSION 
The presented identification algorithm is simple, easy to implement, and of a reduced 
memory size and execution time. Its efficiency was proved by a great number of numerical 
tests. The identification results may probably be improved by the use of a second-order 
descent method. 
It seems interesting to compare a drug administration by two different ways: stomach 
and duodenum for a prodrug and its metabolite. 
Dosing the only metabolite it is possible to obtain by difference the metabolic clearance 
of a drug. This method makes it possible to escape to measure acetylsalicylate in blood 
which is metabolised in a few minutes. This work does not present all the obtained results 
but wants to be a methodologic pathway. 
It was possible to improve the understanding of the time course of aspirin in rabbit in 
comparison to the time course of its main metabolite, the sodium salicylate, and this for 
the same animal. 
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